Key clinical point:
Major finding: At a median time of study of 8.9 months, the overall response rate among all treated patients was 68%.
Study details: Follow-up of a phase 1b dose-escalation and expansion cohort of 145 patients aged 65 years and older with treatment-naive AML.
Disclosures: The trial was supported by AbbVie and Genentech. Dr. DiNardo and multiple coauthors disclosed relationships with AbbVie, Genentech, and other companies.
DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.